TrialClinical pharmacology and therapeutics2022

Combined Conventional Synthetic Disease Modifying Therapy vs. Infliximab for Rheumatoid Arthritis: Emulating a Randomized Trial in Observational Data.

Andrei Barbulescu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.